<scp>COVID</scp>‐19 pandemic and the tension between the need to act and the need to know

Scott, Ian

doi:10.1111/imj.14929

Cited by 7 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned earlier, a pandemic as serious as COVID-19 will compel some clinicians and patients to try unproven therapies based on theory, in vitro data, animal models, clinical anecdotes, observational studies and uncontrolled trials that may later be shown to be misleading [ 40 ]. This leads to multiple small, non-controlled and non-randomised trials that would not generate the strong evidence needed to determine the relative effectiveness of potential treatments [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Disputes over the production and dissemination of misinformation in the time of COVID-19

Cazzola

Novellis

Bianco

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

Ultimate coronavirus disease 2019 (COVID-19) mitigation and crisis resolution is dependent on trustworthy data and actionable information. At present time, there is still no cure for COVID-19, although some treatments are being used in severe illness. Regrettably, as the SARS‐CoV‐2 virus spreads, the lack of cure has been accompanied by an increasing amount of medical misinformation. In particular, there is a lot of misinformation about how to treat patients who have tested positive for SARS‐CoV‐2 and who are asymptomatic or have mild symptoms and for whom management at home is deemed appropriate. In this article, we highlight the risks deriving from this misinformation, which often arises from the publication of studies that are not conceptually and methodologically accurate.

show abstract

Section: Discussionmentioning

confidence: 99%

Disputes over the production and dissemination of misinformation in the time of COVID-19

Cazzola

Novellis

Bianco

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…Although the rapid translation of COVID-related medical research is essential, it is balanced by the ‘false promise of rushed science [ 33 ▪▪ ].’ There are already several hundred COVID-19 trials registered across the world, and this number is increasing exponentially. The increase in preprint publication servers allows for dissemination of nonpeer-reviewed research, which can be publicized and reported prior to appropriate scrutiny of results and conclusions.…”

Section: Be a Critical Readermentioning

confidence: 99%

“…The increase in preprint publication servers allows for dissemination of nonpeer-reviewed research, which can be publicized and reported prior to appropriate scrutiny of results and conclusions. Concerns have been raised about publication of small case series, or randomized controlled trials that have small samples from a single center, which ‘at any other time would be hypothesis generating’ now receiving significant weight and attention [ 33 ▪▪ ].…”

Section: Be a Critical Readermentioning

confidence: 99%

“…An inclination for journals to quickly publish novel findings related to COVID-19 along with a need for rapid dissemination of information has resulted in fast-tracked publication reviews, and some notable retractions [ 33 ▪▪ ]. A cross-sectional analysis of 1551 registered COVID-19 studies noted that the majority of studies were single center, only 29.3% of randomized controlled trials were placebo-controlled, and only 29.1% could yield level 2 evidence [ 34 ▪▪ ].…”

Section: Be a Critical Readermentioning

confidence: 99%

See 1 more Smart Citation

Ten tips for improving your clinical practice during the COVID-19 pandemic

Abrams

Singer

Greenhawt

et al. 2021

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of review This review provides ten tips for improving clinical practice during COVID-19 as pandemic fatigue begins to complicate personal and professional lives of clinicians. Recent findings COVID-19 has created unique and unexpected challenges to healthcare delivery, but has also provided opportunities for re-evaluation of practice patterns to optimize high-value practices. With ongoing uncertainty, key factors to appreciate for patient and population health include the continued touchstones of empathy and compassion, the use of effective risk communication with shared clinical decision-making when appropriate, attention to resource stewardship and vulnerable populations, importance of health literacy and need for critical assessment of media and medical literature to mitigate misinformation, and the hidden costs of the pandemic on children. Although there has been some international concern for allergic reactions to the recently approved Pfizer-BioNTech COVID-19 vaccine, neither the United States Pfizer-BioNTech or Moderna COVID-19 vaccine emergency use authorizations exclude patients without a specific allergy to a vaccine component from receiving vaccination. Summary Practical adjustments to practice during COVID-19 are feasible and acceptable. Experience during COVID-19 reinforces the critical need for human connection while providing care and service in every encounter.

show abstract

“…Some adaptive designs may improve efficiency, confer health benefits to trial participants, or in some cases achieve both (Burnett et al, 2020;Pallmann et al, 2018), including in the context of COVID-19 treatment trials (Stallard et al, 2020) and of vaccine trials (Kahn et al, 2021). Response-adaptive randomisation (RAR), in which the proportion of people randomised to a particular trial arm is modified based on accumulated data observed at an interim analysis, has been suggested (Kahn et al, 2021;Scott, 2020) to have the potential to balance the competing objectives of health benefits to the trial participants, power and time until A c c e p t e d M a n u s c r i p t a conclusion is reached. Brueckner et al (2018) compared different RAR designs for trials of treatments during an epidemic.…”

Section: Introductionmentioning

confidence: 99%